Sign inJoin waitlistJoin the waitlist

Ahmed Khalid

CAMC Employed · Charleston Area Medical Center

Credentials: · · · ·

History

Charleston Area Medical Center
Present

Hematology and Medical Oncology
UAMS Medical Center
1994–1997
Mount Sinai Health System
1991–1994
Columbia University
1988–1991
RAWALPINDI MED COLL, RAWALPINDI
1984–1988

Research

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN…
The Lancet Oncology · 2016 · 116 citations
A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors
Frontiers in Oncology · 2021 · 11 citations
Flow Cytometric Enumeration of Peripheral Blood CD34+ Cells Predicts Bone Marrow Pathology in Patients with Less Than 1% Blasts by Manual Count
Journal of Blood Medicine · 2023 · 9 citations

TJ
Tomislav Jelic
3 papers
Oscar Estalilla
2 papers
Andrew Plata
1 paper · 1 as a resident
Ayodele Adelanwa
1 paper · 1 as a fellow
David Carbone
1 paper
Farzeen Syed
1 paper · 1 as a resident
GG
Gregory Gerstner
1 paper
Heather Wakelee
1 paper
JV
Jeffrey Vos
1 paper
JR
Jerome Rubin
1 paper
Joel Neal
1 paper
Lin Mei
1 paper

Clinical trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2031
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030